Patents by Inventor Johann Leban

Johann Leban has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10633369
    Abstract: The present invention relates to a DYRK1B inhibitor for use in the treatment of cancer, wherein in said cancer and/or in cells of said cancer the hedgehog signaling pathway is activated, and in particular the activation of the hedgehog signaling pathway is independent of signaling by the G protein-coupled receptor Smoothened.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: April 28, 2020
    Assignee: 4 SC AG
    Inventors: Fritz Aberger, Wolfgang Gruber, Johann Leban, Hella Kohlhof, Daniel Vitt, Roland Baumgartner
  • Patent number: 10221147
    Abstract: The present disclosure relates to a chemical compound having the general formula wherein R1 and R2 are, equal or independently, aryl, heteroaryl; wherein RTA is a 2-1,3-, or 4-1,3- or 5-1,3-thiazole ring and its use in for improving the short term memory and/or the working memory.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: March 5, 2019
    Assignee: Red Bull GmbH
    Inventors: Johann Leban, Gert Lubec
  • Publication number: 20180201606
    Abstract: The present invention relates to a DYRK1B inhibitor for use in the treatment of cancer, wherein in said cancer and/or in cells of said cancer the hedgehog signaling pathway is activated, and in particular the activation of the hedgehog signaling pathway is independent of signaling by the G protein-coupled receptor Smoothened.
    Type: Application
    Filed: March 8, 2018
    Publication date: July 19, 2018
    Applicant: 4 SC AG
    Inventors: Fritz ABERGER, Wolfgang GRUBER, Johann LEBAN, Hella KOHLHOF, Daniel VITT, Roland BAUMGARTNER
  • Patent number: 10005769
    Abstract: The present invention relates to compounds of below Formula (I), physiologically functional derivatives or salts thereof, where the groups R1, R2, R3, R4, RA, X1, and A, as well as the variables n, m and p are detailed further herein. In another aspect, the present invention provides methods for their preparation, their medical use and pharmaceutical compositions comprising said compounds, physiologically functional derivatives, solvates or salts thereof.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: June 26, 2018
    Assignee: 4SC AG
    Inventors: Johann Leban, Mirko Zaja
  • Patent number: 9951050
    Abstract: The present invention relates to a DYRK1B inhibitor for use in the treatment of cancer, wherein in said cancer and/or in cells of said cancer the hedgehog signaling pathway is activated, and in particular the activation of the hedgehog signaling pathway is independent of signaling by the G protein-coupled receptor Smoothened.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: April 24, 2018
    Assignee: 4 SC AG
    Inventors: Fritz Aberger, Wolfgang Gruber, Johann Leban, Hella Kohlhof, Daniel Vitt, Roland Baumgartner
  • Publication number: 20170240556
    Abstract: The invention relates to a compound of the general formula (I) or a physiologically functional derivative, solvate or salt thereof, wherein A is a bond, alkyl or alkoxy optionally substituted with one or more R? as defined herein, *—N(R??)CO—, *—CON(R??)—, *—N(R??)CON(R??)—, —S—, —SO—, *—N(R??)—, *—N(R??)CO—, *—CON(R??)—, —CO—, *—COO—, *—OOC—, *—SO2N(R??)—, —SO2, or *—N(R??)—SO2—, wherein R?? is as defined herein and * specifies the point of attachment to X; X is aryl, cycloalkyl, aralkyl, heterocyclyl or heteroaryl, which may be substituted with one or more RX further described herein; L is a bond or *—N(RN)CO—, *—CON(RN)—, *—N(RN)—, *—C?N(RN)—, *—N(RN)-alkyl-, *-alkyl-N(RN)—, *—N(RN)CON(RN)—, *—CO—, *—CO2—, alkyl, *-alkyl-O-alkyl-, *—NCO—CH?CH—, *—CH?CH—CONH—, *—SO2N(RN)—, *—N(RN)SO2—, or heterocyclyl, wherein * specifies the point of attachment to X; Y is H, alkyl, aryl, aralkyl, cycloalkyl, heterocyclyl or heteroaryl, which may be substituted with one or more RY further described herein; and R and RN
    Type: Application
    Filed: February 27, 2017
    Publication date: August 24, 2017
    Applicant: 4SC DISCOVERY GMBH
    Inventors: Johann LEBAN, Mirko ZAJA
  • Publication number: 20170174642
    Abstract: The present disclosure relates to a chemical compound having the general formula wherein R1 and R2 are, equal or independently, aryl, heteroaryl; wherein RTA is a 2-1,3-, or 4-1,3- or 5-1,3-thiazole ring and its use in for improving the short term memory and/or the working memory.
    Type: Application
    Filed: February 10, 2017
    Publication date: June 22, 2017
    Inventors: Johann Leban, Gert Lubec
  • Patent number: 9580438
    Abstract: The invention relates to a compound of the general formula (I) or a physiologically functional derivative, solvate or salt thereof, wherein A, X, L, Y, R, and RN are as defined herein. The invention further relates to the use of the compounds of formula (I) as a medicament, a pharmaceutical composition comprising them, a method of treatment or prevention of a medical condition entailing the administration thereof, and the use thereof in the manufacture of a medicament for the treatment or prevention of a medical condition, particularly autoimmune inflammatory disorders, CNS disorders, sleeping disorders, or proliferative diseases including cancer. The invention further relates to a specific process for the preparation of said compounds.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: February 28, 2017
    Assignee: 4SC DISCOVERY GMBH
    Inventors: Johann Leban, Mirko Zaja
  • Publication number: 20160137637
    Abstract: The present invention relates to compounds of below Formula (I), physiologically functional derivatives or salts thereof, where the groups R1, R2, R3, R4, RA, X1, and A, as well as the variables n, m and p are detailed further herein. In another aspect, the present invention provides methods for their preparation, their medical use and pharmaceutical compositions comprising said compounds, physiologically functional derivatives, solvates or salts thereof.
    Type: Application
    Filed: June 17, 2014
    Publication date: May 19, 2016
    Applicant: 4SC DISCOVERY GMBH
    Inventors: Johann LEBAN, Mirko ZAJA
  • Publication number: 20150158878
    Abstract: The invention relates to a compound of the general formula (I) or a physiologically functional derivative, solvate or salt thereof, wherein A, X, L, Y, R, and RN are as defined herein. The invention further relates to the use of the compounds of formula (I) as a medicament, a pharmaceutical composition comprising them, a method of treatment or prevention of a medical condition entailing the administration thereof, and the use thereof in the manufacture of a medicament for the treatment or prevention of a medical condition, particularly autoimmune inflammatory disorders, CNS disorders, sleeping disorders, or proliferative diseases including cancer. The invention further relates to a specific process for the preparation of said compounds.
    Type: Application
    Filed: June 27, 2013
    Publication date: June 11, 2015
    Applicant: 4SC DISCOVERY GMBH
    Inventors: Johann Leban, Mirko Zaja
  • Publication number: 20140371251
    Abstract: The present invention relates to a DYRK1B inhibitor for use in the treatment of cancer, wherein in said cancer and/or in cells of said cancer the hedgehog signaling pathway is activated, and in particular the activation of the hedgehog signaling pathway is independent of signaling by the G protein-coupled receptor Smoothened.
    Type: Application
    Filed: June 18, 2014
    Publication date: December 18, 2014
    Applicant: 4SC DISCOVERY GMBH
    Inventors: Fritz ABERGER, Wolfgang GRUBER, Johann LEBAN, Hella KOHLHOF, Daniel VITT, Roland BAUMGARTNER
  • Patent number: 8653138
    Abstract: The present invention relates to calcium salts of compounds of the general formula (I) wherein X is selected from the group consisting of CH2, S, or O; D is O or S; R8 is hydrogen or alkyl; E is an optionally substituted phenylene group; Y is a monocyclic or bicyclic substituted or unsubstituted 6-9 membered ring system which may contain one or more heteroatoms selected from N or S and which contains at least one aromatic ring; n is 0 or 1, and q is 0 or 1; with the proviso that compounds wherein X?CH2, q=0, Y=unsubstituted phenyl and E=unsubstituted phenylene are excluded; or a hydrate thereof.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: February 18, 2014
    Assignee: 4SC MG
    Inventors: Aldo Ammendola, Julia Diederichs, Johann Leban, Daniel Vitt
  • Patent number: 8592456
    Abstract: The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: November 26, 2013
    Assignee: 4SC Discovery GmbH
    Inventors: Johann Leban, Stefan Tasler, Roland Baumgartner, Wael Saeb, Carine Chevrier
  • Patent number: 8354433
    Abstract: The present invention relates to compounds of the general formula (I) and salts and physiologically functional derivatives thereof, for the use as a medicament.
    Type: Grant
    Filed: May 3, 2010
    Date of Patent: January 15, 2013
    Assignee: 4SC AG
    Inventors: Daniel Vitt, Manfred Groeppel, Roland Baumgartner, Johann Leban
  • Patent number: 8354436
    Abstract: The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: January 15, 2013
    Assignee: 4SC Discovery GmbH
    Inventors: Johann Leban, Stefan Tasler, Wael Saeb, Carine Chevrier
  • Publication number: 20120196862
    Abstract: The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents.
    Type: Application
    Filed: January 27, 2012
    Publication date: August 2, 2012
    Applicant: 4SC Discovery GmbH
    Inventors: Johann LEBAN, Stefan TASLER, Wael SAEB, Carine CHEVRIER
  • Publication number: 20120196861
    Abstract: The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents.
    Type: Application
    Filed: January 27, 2012
    Publication date: August 2, 2012
    Applicant: 4SC Discovery GmbH
    Inventors: Johann LEBAN, Stefan TASLER, Roland BAUMGARTNER, Wael SAEB, Carine CHEVRIER
  • Publication number: 20120035175
    Abstract: The present invention relates to a salt selected from the group comprising the N-methyl-D-glucamine salt (NMG), the diethylamine salt (DEA) salt, the magnesium salt, the tromethamine salt, the choline salt, the L-arginine salt, the zinc salt, and the 4-(2-hydroxyethyl)morpholine (HEM) salt of compounds of the general formula (I) wherein X is selected from the group consisting of CH2, S, or O; D is O or S; R8 is hydrogen or alkyl; E is an optionally substituted phenylene group; Y is a monocyclic or bicyclic substituted or unsubstituted 6-9 membered ring system which may contain one or more heteroatoms selected from N or S and which contains at least one aromatic ring; n is 0 or 1; and q is 0 or 1; with the proviso that compounds wherein X?CH2, q=0, Y=unsubstituted phenyl and E=unsubstituted phenylene are excluded; or a hydrate thereof.
    Type: Application
    Filed: July 1, 2011
    Publication date: February 9, 2012
    Applicant: 4SC AG
    Inventors: Aldo AMMENDOLA, Julia DIEDERICHS, Johann LEBAN, Daniel VITT
  • Publication number: 20120028985
    Abstract: The present invention relates to the treatment and prevention of immunological and inflammatory disorders with a compound of formula (I) in combination with methotrexate,
    Type: Application
    Filed: November 6, 2009
    Publication date: February 2, 2012
    Applicant: 4SC AG
    Inventors: Manfred Gröppel, Johann Leban
  • Publication number: 20120029034
    Abstract: The present invention relates to calcium salts of compounds of the general formula (I) wherein X is selected from the group consisting of CH2, S, or O; D is O or S; R8 is hydrogen or alkyl; E is an optionally substituted phenylene group; Y is a monocyclic or bicyclic substituted or unsubstituted 6-9 membered ring system which may contain one or more heteroatoms selected from N or S and which contains at least one aromatic ring; n is 0 or 1, and q is 0 or 1; with the proviso that compounds wherein X?CH2, q=0, Y=unsubstituted phenyl and E=unsubstituted phenylene are excluded; or a hydrate thereof.
    Type: Application
    Filed: July 1, 2011
    Publication date: February 2, 2012
    Applicant: 4SC AG
    Inventors: Aldo AMMENDOLA, Julia DIEDERICHS, Johann LEBAN, Daniel VITT